EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S. Smolen*, Robert B. M. Landewe, Johannes W. J. Bijlsma, Gerd R. Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald F. van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, John Askling, Alejandro Balsa, Maarten Boers, Alfons A. den Broeder, Maya H. Buch, Frank Buttgereit, Roberto Caporali, Mario Humberto CardielDiederik De Cock, Catalin Codreanu, Maurizio Cutolo, Christopher John Edwards, Yvonne van Eijk-Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques-Eric Gottenberg, Merete Lund Hetland, Tom W. J. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Mueller-Ladner, Eduardo F. Mysler, Jose A. P. da Silva, Gyula Poor, Janet E. Pope, Andrea Rubbert-Roth, Adeline Ruyssen-Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, Rene Westhovens, Desiree van der Heijde

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)685-699
Number of pages15
JournalAnnals of the Rheumatic Diseases
Volume79
Issue number6
DOIs
Publication statusPublished - Jun 2020

Keywords

  • TREAT-TO-TARGET
  • INTERLEUKIN-6 RECEPTOR INHIBITION
  • CONSENSUS-BASED RECOMMENDATIONS
  • RAPID RADIOGRAPHIC PROGRESSION
  • DOSE GLUCOCORTICOID THERAPY
  • TREATMENT STRATEGIES
  • REMISSION INDUCTION
  • CERTOLIZUMAB PEGOL
  • RHEUMATOLOGY/EUROPEAN LEAGUE
  • AMERICAN-COLLEGE

Cite this